Get the Stockscreener App
48.71
0.57%
-0.2937
Harrow Inc stock is traded at $48.71, with a volume of 371.07K.
It is down -0.57% in the last 24 hours and up +21.28% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$49.00
Open:
$49.05
24h Volume:
371.07K
Relative Volume:
0.55
Market Cap:
$1.81B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-50.74
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-2.74%
1M Performance:
+21.28%
6M Performance:
+59.37%
1Y Performance:
+33.26%
1-Day Range:
$46.58
$49.30
1-Week Range:
$46.58
$51.53
52-Week Range:
$20.85
$51.53
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
48.74 | 1.81B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
125.41 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.48 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow (NASDAQ:HROW) Hits New 1-Year HighTime to Buy? - MarketBeat
Harrow Health stock hits 52-week high at 51.38 USD - Investing.com
Harrow Health stock hits 52-week high at 51.38 USD By Investing.com - Investing.com UK
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Brookstone Capital Management Grows Stock Holdings in Harrow, Inc. $HROW - MarketBeat
Harrow, Inc. $HROW Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Harrow (NASDAQ:HROW) Has A Somewhat Strained Balance Sheet - 富途牛牛
Squarepoint Ops LLC Has $640,000 Stock Holdings in Harrow, Inc. $HROW - MarketBeat
First Week of February 2026 Options Trading For Harrow (HROW) - Nasdaq
Is Harrow Inc. stock vulnerable to regulatory risksJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - bolumsonucanavari.com
Will Harrow Inc. stock gain from strong economyAnalyst Downgrade & Stepwise Trade Signal Guides - Улправда
What margin trends mean for Harrow Inc. stockQuarterly Portfolio Summary & Long-Term Capital Growth Strategies - DonanımHaber
Why Harrow Inc. stock appeals to dividend seekersJuly 2025 Intraday Action & Real-Time Volume Trigger Notifications - Улправда
Insider Buy: Can Harrow Inc. stock resist market sell offsRate Hike & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Harrow Inc. stock attractive for income investorsMarket Performance Report & Consistent Growth Equity Picks - Улправда
CFO Boll Acquires 33,335 Of Harrow Inc [HROW] - TradingView — Track All Markets
Harrow (HROW) CEO Mark Baum exercises 180,000 stock options in company - Stock Titan
Harrow (NASDAQ:HROW) Trading Down 5.8%Should You Sell? - MarketBeat
Braidwell LP Trims Holdings in Harrow, Inc. $HROW - MarketBeat
Harrow (NASDAQ:HROW) Reaches New 52-Week HighWhat's Next? - MarketBeat
Harrow Health stock hits 52-week high at 50.75 USD - Investing.com
Harrow, Inc. $HROW Shares Bought by Marshall Wace LLP - MarketBeat
Precision Trading with Harrow Health Inc. 11.875% Senior Notes Due 2027 (HROWM) Risk Zones - Stock Traders Daily
Divisadero Street Capital Management LP Takes Position in Harrow, Inc. $HROW - MarketBeat
Aug Closing: Why Harrow Inc stock is favored by pension funds2025 Performance Recap & Daily Entry Point Trade Alerts - moha.gov.vn
Harrow (HROW) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How the Narrative Surrounding Harrow Is Evolving After Analyst Target Upgrades - Yahoo Finance
Can Harrow Inc. stock deliver strong Q4 earningsLong Setup & Safe Capital Growth Stock Tips - Newser
Panagora Asset Management Inc. Acquires Shares of 47,132 Harrow, Inc. $HROW - MarketBeat
155,465 Shares in Harrow, Inc. $HROW Acquired by Diametric Capital LP - MarketBeat
Harrow (NASDAQ:HROW) Shares Up 10.2%Time to Buy? - MarketBeat
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story - Yahoo Finance
Should Vevye’s CVS Formulary Win Prompt a Closer Look from Harrow (HROW) Investors? - simplywall.st
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW) - Seeking Alpha
Creative Planning Grows Holdings in Harrow, Inc. $HROW - MarketBeat
Harrow, Inc. $HROW Shares Purchased by Geode Capital Management LLC - MarketBeat
Intech Investment Management LLC Sells 6,798 Shares of Harrow, Inc. $HROW - MarketBeat
Insider Sell: Why Harrow Inc. stock appeals to dividend seekersMarket Trend Review & Weekly High Return Stock Opportunities - moha.gov.vn
Market Trends: Is Harrow Inc. stock attractive for income investors - moha.gov.vn
How Harrow Health Inc. 8.625% Senior Notes Due 2026 (HROWL) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Harrow to Present at Two Investor Conferences in December - Sahm
Following a 2.8% Decline Over Last Year, Recent Gains May Please Harrow, Inc. (NASDAQ:HROW) Institutional Owners - 富途牛牛
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% - Yahoo Finance
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge - The Motley Fool
A Fresh Look at Harrow (HROW) Valuation Following Recent Revenue Growth and Long-Term Performance - Yahoo Finance
Why Harrow Inc. stock remains on watchlistsJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Health Care Notes: Analysts raise HCA price targets - Nashville Post
Should I hold or sell Harrow Inc. stock in 2025Portfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
Harrow, Inc. Hits Day High with 7.65% Surge in Strong Intraday Performance - Markets Mojo
How Harrow Inc. stock performs in rising dollar environment2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
| SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):